Intra-Cellular Therapies, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-38
RECRUITING11
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO44%
Delay Index: of 9 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +4.4 months). See all sponsors →
Open Intra-Cellular Therapies, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ITI-1284 10 mg NCT06480383 |
P2 | Recruiting | Generalized Anxiety Disorder | 705 | 2027-03-16 (+3 mo) |
| Lumateperone NCT05850689 |
P3 | Recruiting | Major Depressive Disorder | 470 | 2027-04-05 (+18 mo) |
| Lumateperone high dose NCT06706674 |
P3 | Recruiting | Irritability Associated With Autism Spectrum Disorder | 160 | 2027-06-21 (+4 mo) |
| Lumateperone high dose NCT06690398 |
P3 | Recruiting | Irritability Associated With Autism Spectrum Disorder | 160 | 2027-06-21 (+4 mo) |
| ITI-1284 10 mg NCT06701903 |
P2 | Recruiting | Generalized Anxiety Disorder | 570 | 2027-10-14 (+4 mo) |
| ITI-1284 NCT06651567 |
P2 | Recruiting | Agitation Associated With Alzheimer's Dementia | 320 | 2027-12-28 (+3 mo) |
| ITI-1284 NCT06540833 |
P2 | Recruiting | Psychotic Disorders; Alzheimer Disease | 370 | 2028-09-30 (+13 mo) |
| CANDLE NCT07747389 |
P3 | Not yet recruiting | Depressive Disorder, Major | 585 | 2029-09-20 |
| ITI-1284 NCT07807865 |
P3 | Recruiting | Generalized Anxiety Disorder | 900 | 2030-02-18 |
| JNJ-99245354 NCT07856420 |
P3 | Recruiting | Generalized Anxiety Disorder | 705 | 2030-09-20 |
| Lumateperone NCT06372964 |
P3 | Recruiting | Bipolar Depression | 384 | 2031-10-31 (+55 mo) |
| Lumateperone NCT06229210 |
P3 | Recruiting | Schizophrenia; Bipolar Disorder | 300 | 2032-04-28 (+53 mo) |